Candel Therapeutics Ownership | Who Owns Candel Therapeutics?


OverviewRevenueFinancialsChart

Candel Therapeutics Ownership Summary


Candel Therapeutics is owned by 20.91% institutional investors, 30.39% insiders, and 48.71% retail investors. Northpond ventures is the largest institutional shareholder, holding 6.63% of CADL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.69% of its assets in Candel Therapeutics shares.

CADL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCandel Therapeutics20.91%30.39%48.71%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Northpond ventures1.94M6.63%$12.00M
Blackrock823.07K2.82%$5.10M
Vanguard group818.55K2.80%$5.08M
State street472.80K1.62%$2.93M
Sands capital ventures405.84K1.39%$2.52M
Geode capital management397.89K1.36%$2.47M
Nuveen asset management382.19K1.31%$2.37M
Bridgeway capital management80.59K0.28%$499.69K
Mml investors services73.38K0.25%$455.00K
Bank of america corp /de/54.45K0.19%$337.58K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Northpond ventures1.94M21.71%$12.00M
Sands capital ventures405.84K0.84%$2.52M
Bridgeway capital management80.59K0.01%$499.69K
Virtu financial22.64K0.01%$140.00K
Mml investors services73.38K0.00%$455.00K
Cubist systematic strategies26.12K0.00%$161.95K
Nuveen asset management382.19K0.00%$2.37M
Corebridge financial10.66K0.00%$66.20K
Vontobel22.00K0.00%$136.40K
Ameritas investment partners1.94K0.00%$12.03K

Top Buyers

HolderShares% AssetsChange
Blackrock823.07K0.00%775.49K
State street472.80K0.00%445.20K
Nuveen asset management382.19K0.00%382.19K
Vanguard group818.55K0.00%277.25K
Geode capital management397.89K0.00%252.18K

Top Sellers

HolderShares% AssetsChange
Sands capital ventures405.84K0.84%-405.90K
Mariner---33.48K
Resources investment advisors, llc.---29.78K
Advisor group---25.80K
Schonfeld strategic advisors---21.45K

New Positions

HolderShares% AssetsChangeValue
Nuveen asset management382.19K0.00%382.19K$2.37M
Mml investors services73.38K0.00%73.38K$455.00K
Bank of new york mellon54.45K0.00%54.45K$337.58K
Charles schwab investment management46.78K0.00%46.78K$290.02K
Cubist systematic strategies26.12K0.00%26.12K$161.95K

Sold Out

HolderChange
Qube research-1.00
Point72 asia (singapore) pte.-813.00
Point72 (difc)-4.93K
Two sigma investments, lp-13.41K
Commonwealth equity services-14.18K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20245614.29%6,693,23112.27%205.01%31-26.19%10150.00%
Jun 30, 202449157.89%5,961,76157.71%2011.96%42366.67%4-20.00%
Mar 31, 202419-9.52%3,780,258-6.13%136.74%9-5-
Dec 31, 20232110.53%4,027,160-23.41%134.21%950.00%5-
Sep 30, 202319-5,257,852-2.09%185.27%620.00%5-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv543.64K1.69%89.83K
iShares Russell 2000 ETF511.78K1.60%-1.15K
BANOR SICAV Rosemary S EUR Acc398.83K1.24%-
Vanguard Institutional Extnd Mkt Idx Tr220.07K0.69%-
State St Russell Sm/Mid Cp® Indx NL Cl C218.40K0.68%-4.10K
Fidelity Small Cap Index203.68K0.63%-5.77K
iShares Russell 2000 Growth ETF178.36K0.56%-
Aesculape SRI IC135.75K0.42%-
Fidelity Extended Market Index114.33K0.36%24.40K
Vanguard US Momentum Factor ETF97.22K0.30%97.22K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 16, 2024Manning Paul B-Buy$4.50M
Dec 16, 2024Manning Paul B-Buy$3.00M
Nov 29, 2024Tyagarajan Seshu Chief Technology OfficerSell$92.90K
Nov 29, 2024Tak Paul Peter Chief Executive OfficerSell$222.53K
Nov 29, 2024Nichols William Garrett Chief Medical OfficerSell$63.48K

Insider Transactions Trends


DateBuySell
2024 Q4210
2024 Q3-10
2024 Q2--
2024 Q1--
2023 Q4--

CADL Ownership FAQ


Who Owns Candel Therapeutics?

Candel Therapeutics shareholders are primarily institutional investors at 20.91%, followed by 30.39% insiders and 48.70% retail investors. The average institutional ownership in Candel Therapeutics's industry, Biotech Stocks , is 47.04%, which Candel Therapeutics falls below.

Who owns the most shares of Candel Therapeutics?

Candel Therapeutics’s largest shareholders are Northpond ventures (1.94M shares, 6.63%), Blackrock (823.07K shares, 2.82%), and Vanguard group (818.55K shares, 2.80%). Together, they hold 12.25% of Candel Therapeutics’s total shares outstanding.

Does Blackrock own Candel Therapeutics?

Yes, BlackRock owns 2.82% of Candel Therapeutics, totaling 823.07K shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.1M$. In the last quarter, BlackRock increased its holdings by 775.49K shares, a 1629.87% change.

Who is Candel Therapeutics’s biggest shareholder by percentage of total assets invested?

Northpond ventures is Candel Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.71% of its assets in 1.94M Candel Therapeutics shares, valued at 12M$.

Who is the top mutual fund holder of Candel Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Candel Therapeutics shares, with 1.69% of its total shares outstanding invested in 543.64K Candel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools